Fusen Pharmaceutical Company Limited (Fusen Pharm) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited, has obtained marketing approval from the National Medical Products Administration (NMPA) for “Lornoxicam for Injection” aimed at the short-term treatment of moderate acute post-operative pain.

Lornoxicam, a non-steroidal thienothiazine derivative, delivers strong analgesic and anti-inflammatory effects by inhibiting Cyclooxygenase activity and activating the opioid neuropeptide pathway. The injectable formulation offers post-operative pain relief comparable to morphine but with a lower incidence of respiratory depression, nausea, vomiting, and addiction risks associated with opioids.

The product is classified as a Class B drug under the National Healthcare Security Administration reimbursement list and is recommended in several authoritative domestic guidelines, including the Expert Consensus on Postoperative Pain Management in Adults. According to Menet data, aggregate sales of Lornoxicam for Injection across China’s three major terminal channels and six major markets exceeded RMB300.00 million in 2025.

Management stated that the launch of Lornoxicam for Injection expands Fusen Pharm’s anti-inflammatory and analgesic portfolio and provides additional perioperative pain-management options for patients.

The company’s board of directors is chaired by Mr. Cao Zhiming. The announcement was released on 11 May 2026 in Hong Kong.